Avalo Therapeutics, Inc.(AVTX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Avalo Therapeutics, Inc. (AVTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVTX at 11.7/100 on a 32-signal composite quality model, placing it at rank #2,897 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (0.2) and profitability (0.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.1/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of AVTX by reported 13-F value include FMR, BlackRock, Deep Track Capital, based on the most recent SEC filings. AVTX trades on the Nasdaq exchange and files with the SEC under CIK 1534120. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Avalo Therapeutics, Inc. directly from SEC EDGAR.

AI Quality Score

11.7/100

AI Rank

#2,897

Net Income

$-36.4M

AVTX key financials by period

Avalo Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$59.0K$-78.3M—
FY 202410-K$441.0K$-35.1M—
FY 202310-K$1.9M$-31.5M—
FY 202210-K$18.1M$-41.7M—
FY 202110-K$5.4M$-84.4M—
FY 202010-K$6.7M$-63.5M—

Institutions holding AVTX

Institutional investors reporting a position in Avalo Therapeutics, Inc. on SEC Form 13F.
InstitutionSharesValueReported
FMR5,100,216$94.3M2026-06-30
BlackRock4,365,553$80.7M2026-06-30
Deep Track Capital3,610,000$66.7M2026-06-30
Caligan Partners3,163,866$58.5M2026-06-30
TCG Crossover Management3,017,120$55.8M2026-06-30
Affinity Asset Advisors2,900,000$53.6M2026-06-30
STATE STREET2,889,287$53.4M2026-06-30
FARALLON CAPITAL MANAGEMENT2,498,000$46.2M2026-06-30
Point72 Asset Management, L.P.2,387,026$44.1M2026-06-30
Avoro Capital Advisors2,333,333$43.1M2026-06-30
SEC EDGAR: CIK 1534120 →
AVTX

Avalo Therapeutics, Inc.

AVTX
NasdaqSmall CapHealthcare

13F Pro Quality Score

11.7/100

Rank #2,897 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

0.3/100

Balance Sheet

7.0/100

Earnings Quality

28.1/100

Free Cash Flow

0.3/100

Institutional Flow

37.7/100

Revenue Scale

0.2/100

Dilution Risk

0.1/100

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-36.36M

EPS (Diluted)

Q2 2026
EDGAR

$-0.83

ROIC

Q2 2026
EDGAR

-28.1%

Top Institutional Holders

as of Q2 2026
$1.33B total
FMR LLC
$94.25M+77.1%
BlackRock, Inc.
$80.68M+1234.7%
Deep Track Capital, LP
$66.71MNew
Caligan Partners LP
$58.47M+93.5%
TCG Crossover Management, LLC
$55.76M+308.6%
Affinity Asset Advisors, LLC
$53.59M+116.3%
STATE STREET CORP
$53.39M+3932.3%
FARALLON CAPITAL MANAGEMENT LLC
$46.16M+172.7%
Point72 Asset Management, L.P.
$44.11M+160.6%
Avoro Capital Advisors LLC
$43.12M+65.5%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…